Alterations in the cholinesterase and adenosine deaminase activities and inflammation biomarker levels in patients with multiple sclerosis

Neuroscience

Volumn 266, Issue , 2014, Pages 266-274

  Polachini, C R N ^a   Spanevello, R M ^b   Casali, E A ^c   Zanini, D ^a   Pereira, L B ^a   Martins, C C ^a   Baldissareli, J ^a   Cardoso, A M ^a   Duarte, M F ^d   da Costa, P ^a   Prado, A L C ^a   Schetinger, M R C ^a   Morsch, V M ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

Author keywords

Adenosine deaminase; Cholinesterases; Cytokines; Inflammation; Lymphocytes; Multiple sclerosis

Indexed keywords

ADENOSINE DEAMINASE; BIOLOGICAL MARKER; CHOLINESTERASE;

ADULT; BLOOD; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; YOUNG ADULT;

ADENOSINE DEAMINASE; ADULT; BIOLOGICAL MARKERS; CHOLINESTERASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; YOUNG ADULT;

EID: 84898857311     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.01.048     Document Type: Article

References (76)

1. Aktas O., Waiczies S., Zipp F. Neurodegeneration in autoimmune demyelination: recent mechanistic insights reveal novel therapeutic targets. J Neuroimmunol 2007, 184:17-26.
2. Bansi J., Bloch W., Gamper U., Kesselring J. Training in MS: influence of two different endurance training protocols (aquatic versus overland) on cytokine and neurotrophin concentrations during three week randomized controlled trial. Mult Scler 2013, 19:613-621.
3. Battisti V., Schetinger M.R., Maders L.D., Santos K.F., Bagatini M.D., Correa M.C., Spanevello R.M., do Carmo Araújo M, Morsch V.M. Changes in acetylcholinesterase (AChE) activity in lymphocytes and whole blood in acute lymphoblastic leukemia patients. Clin Chim Acta 2009, 402:114-118.
4. Bencherif M., Lippiello P.M., Lucas R., Marrero M.B. Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases. Cell Mol Life Sci 2011, 68:931-949.
5. Bergmeyer H.U. Methods of enzymatic analysis 1983, Verlag Chemie, Deerfiled Beach.
6. Bours M.J., Swennen E.L., Di Virgilio F., Cronstein B.N., Dagnelie P.C. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 2006, 112:358-404.
7. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 1968, 97:77-89.
8. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
9. Brück W. Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis. J Neurol 2005, 252:10-15.
10. Cerejeira J., Nogueira V., Luís P., Vaz-Serra A., Mukaetova-Ladinska E.B. The cholinergic system and inflammation: common pathways in delirium pathophysiology. J Am Geriatr Soc 2012, 60:669-675.
11. Cieślak M., Komoszyński M. The role of ecto-purines in inflammation leading to demyelination - new means for therapies against multiple sclerosis. Neurol Neurochir Pol 2011, 45:489-499.
12. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
13. Cordero O.J., Salgado F.J., Fernández-Alonso C.M., Herrera C., Lluis C., Franco R., Nogueira M. Cytokines regulate membrane adenosine deaminase on human activated lymphocytes. J Leukoc Biol 2001, 70:920-930.
14. Costa C.C.R., Fonteles J.L., Praça L.R., Andrade A.C. O adoecimento do portador de esclerose múltipla: percepções e vivências a partir da narrativa de dois casos clínicos. RBPS 2005, 18:117-124.
15. Darvesh S., Leblanc A.M., Macdonald I.R., Reid G.A., Bhan V., Macaulay R.J., Fisk J.D. Butyrylcholinesterase activity in multiple sclerosis neuropathology. Chem Biol Interact 2010, 187:425-431.
16. Das U.N. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Monit 2007, 13:214-221.
17. Das U.N. Is multiple sclerosis a proresolution deficiency disorder?. Nutrition 2012, 28:951-958.
18. De Almeida J.P., Saldanha C. Nonneuronal cholinergic system in human erythrocytes: biological role and clinical relevance. J Membr Biol 2010, 234:227-234.
19. De Oliveira P., Gomes A.Q., Pacheco T.R., Vitorino de Almeida V., Saldanha C., Calado A. Cell-specific regulation of acetylcholinesterase expression under inflammatory conditions. Clin Hemorheol Microcirc 2012, 51:129-137.
20. Dwyer K., Deaglio S., Gao W., Friedman D., Strom T., Robson S. CD39 and control of cellular immune responses. Purinergic Signal 2007, 3:171-180.
21. Ellman G.L., Courtney K.D., Andres V., Feather-stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 7:88-95.
22. Ferrero M.E. Purinoceptors in inflammation: potential as anti-inflammatory therapeutic targets. Front Biosci (Landmark Ed) 2011, 16:2172-2186.
23. Fitzgerald B.B., Costa L.G. Modulation of muscarinic receptors and acetylcholinesterase activity in lymphocytes and in brain areas following repeated organophosphate exposure in rats. Fundam Appl Toxicol 1993, 20:210-216.
24. Franco R., Casadó V., Ciruela F., Saura C., Mallol J., Canela E.I., Lluis C. Cell surface adenosine deaminase: much more than an ectoenzyme. Prog Neurobiol 1997, 52:283-294.
25. Fujii T., Takada-Takatori Y., Kawashima K. Basic and clinical aspects of non-neuronal acetylcholine: expression of an independent, non-neuronal cholinergic system in lymphocytes and its clinical significance in immunotherapy. J Pharmacol Sci 2008, 106:186-192.
26. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454.
27. Gessi S., Varani K., Merighi S., Fogli E., Sacchetto V., Benini A., Leung E., Mac-Lennan S., Borea P.A. Adenosine and lymphocyte regulation. Purinergic Signal 2007, 3:109-116.
28. Goldberg L.D., Edwards N.C., Fincher C., Doan Q.V., Al-Sabbagh A., Meletiche D.M. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009, 15:543-555.
29. Gombault A., Baron L., Couillin I. ATP release and purinergic signaling in NLRP3 inflammasome activation. Front Immunol 2012, 3:414.
30. Goodin D.S., Frohman E.M., Garmany G.P., Halper J., Likosky W.H., Lublin F.D., Silberberg D.H., Stuart W.H., van den Noort S. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002, 58:169-178.
31. Guisti G., Galanti B. Colorimetric method. Methods of enzymatic analysis 1984, 315-323. Verlag Chemie, Weinheim. H.U. Bergmeyer (Ed.).
32. Haskó G., Kuhel D., Chen J., Schwarzschild M.A., Deitch E.A., Mabley J.G., Marton A., Szabó C. Adenosine inhibits IL-12 and TFN-production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J 2000, 14:2065-2074.
33. Hohlfeld R., Kerschensteiner M., Stadelmann C., Lassmann H., Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. Neurol Sci 2006, 27:1-7.
34. Jalilian B., Einarsson H.B., Vorup-Jensen T. Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?. Int J Mol Sci 2012, 13:14579-14605.
35. Jaques J.A., Peres Rezer J.F., Ruchel J.B., Gutierres J., Bairros A.V., Gomes Farias I.L., Almeida da Luz S.C., Cd Mello.Bertoncheli., Chitolina Schetinger M.R., Morsch V.M., Leal D.B. A method for isolation of rat lymphocyte-rich mononuclear cells from lung tissue useful for determination of nucleoside triphosphate diphosphohydrolase activity. Anal Biochem 2011, 410:34-39.
36. Jaques J.A., Rezer J.F., Gonçalves J.F., Spanevello R.M., Gutierres J.M., Pimentel V.C., Thomé G.R., Morsch V.M., Schetinger M.R., Leal D.B. The effect of curcumin in the ectonucleotidases and acetylcholinesterase activities in synaptosomes from the cerebral cortex of cigarette smoke-exposed rats. Cell Biochem Funct 2011, 29:703-707.
37. Jordy S.S., Tilbery C.P., Fazzito M.M. Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases. Arq Neuropsiquiatr 2008, 66:11-14.
38. Karimabad M.N., Arababadi M.K., Hakimizadeh E., Daredori H.Y., Nazari M., Hassanshahi G., Kennedy D. Is the IL-10 promoter polymorphism at position-592 associated with immune system-related diseases?. Inflammation 2013, 36:35-41.
39. Kawashima K., Fujii T. Extraneuronal cholinergic system in lymphocytes. Pharmacol Ther 2000, 86:29-48.
40. Kawashima K., Fujii T. The lymphocytic cholinergic system and its biological function. Life Sci 2003, 72:2101-2109.
41. Kawashima K., Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci 2003, 74:675-696.
42. Killestein J., Den Drijver B.F., Van der Graaff W.L., Uitdehaag B.M., Polman C.H., Van Lier R.A. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease. Mult Scler 2001, 7:145-150.
43. Koch-Henriksen N., Sorensen P.S. Why does the north-south gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere?. J Neurol Sci 2011, 311:58-63.
44. Kurzen H., Wessler I., Kirkpatrick C.J., Kawashima K., Grando S.A. The non-neuronal cholinergic system of human skin. Horm Metab Res 2007, 39:125-135.
45. Langston H.P., Ke Y., Gewirtz A.T., Dombrowski K.E., Kapp J.A. Secretion of IL- 2 and IFN-gamma, but not IL-4, by antigen-specific T cells requires extracellular ATP. J Immunol 2003, 170:2962-2970.
46. Lassmann H. Mechanisms of multiple sclerosis. Drug Discov Today 2005, 2:447-452.
47. Layer P.G., Sporns O. Spatiotemporal relationship of embryonic cholinesterases with cell proliferation in chicken brain and eye. Proc Natl Acad Sci U S A 1987, 84:284-288.
48. Linden J. New insights into the regulation of inflammation by adenosine. J Clin Invest 2006, 116:1835-1837.
49. Mack A., Robitzki A. The key role of butyrylcholinesterase during neurogenesis and neural disorders: an antisense-5'butyrylcholinesterase-DNA study. Prog Neurobiol 2000, 60:607-628.
50. Mazzanti C.M., Spanevello R.M., Pereira L.B., Gonçalves J.F., Kaizer R., Corrêa M., Ahmed M., Mazzanti A., Festugatto R., Graça D.L., Morsch V.M., Schetinger M.R. Acetylcholinesterase activity in rats experimentally demyelinated with ethidium bromide and treated with interferon beta. Neurochem Res 2006, 31:1027-1034.
51. Mazzanti C.M., Spanevello R., Ahmed M., Schmatz R., Mazzanti A., Salbego F.Z., Graça D.L., Sallis E.S., Morsch V.M., Schetinger M.R. Cyclosporine A inhibits acetylcholinesterase activity in rats experimentally demyelinated with ethidium bromide. Int J Dev Neurosci 2007, 25:259-264.
52. Mazzanti C.M., Spanevello R., Ahmed M., Pereira L.B., Gonçalves J.F., Corrêa M., Schmatz R., Stefanello N., Leal D.B., Mazzanti A., Ramos A.T., Martins T.B., Danesi C.C., Graça D.L., Morsch V.M., Schetinger M.R. Pre-treatmant with ebselen and vitamin E modulate acetylcholinesterase activity: interaction with demyelinating agents. Int J Dev Neurosci 2009, 27:73-80.
53. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127.
54. Milo R., Panitch H. Combination therapy in multiple sclerosis. J Neuroimmunol 2011, 231:23-31.
55. Minguetti G. Ressonância Magnética na Esclerose Múltipla, análise de 270 casos. Arq Neuropsiquiatr 2001, 59:563-569.
56. Nizri E., Hamra-Amitay Y., Sicsic C., Lavon I., Brenner T. Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology 2006, 50:540-547.
57. Ofek K., Soreq H. Cholinergic involvement and manipulation approaches in multiple system disorders. Chem Biol Interact 2013, 203:113-119.
58. Porcel J., Montalban X. Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis. J Neurol Sci 2006, 245:177-181.
59. Pratibha K., Anand U., Agarwal R. Serum adenosine deaminase, 5' nucleotidase and malondialdehyde in acute infective hepatitis. Indian J Clin Biochem 2004, 19:128-131.
60. Reipert B. Multiple sclerosis: a short review of the disease and its differences between men and woman. J Mens Health Gend 2004, 1:334-340.
61. Rocha J.B., Emanuelli T., Pereira M.E. Effects of early undernutrition on kinetic parameters of brain acetylcholinesterase from adult rats. Acta Neurobiol Exp (Wars) 1999, 53:431-437.
62. Romeo M., Martinelli-Boneschi F., Rodegher M., Esposito F., Martinelli V., Comi G. Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients. Eur J Neurol 2013, 20:1060-1067.
63. Schetinger M.R., Morsch V.M., Bonan C.D., Wyse A.T. NTPDase and 5'-nucleotidase activities in physiological and disease conditions: new perspectives for human health. Biofactors 2007, 31:77-98.
64. Sellner J., Greeve I., Mattle H.P. Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis. Mult Scler 2008, 14:981-984.
65. Soilu-Hänninen M., Koskinen J.O., Laaksonen M., Hanninen A., Lilius E.M., Waris M. High sensitivity measurement of CRP and disease progression in multiple sclerosis. Neurology 2005, 65:153-155.
66. Spanevello R., Mazzanti C.M., Schmatz R., Bagatini M., Stefanello N., Correa M., Kaizer R., Maldonado P., Mazzanti A., Graça D.L., Martins T.B., Danesi C., Morsch V.M., Schetinger M.R. Effect of vitamin E on ectonucleotidase activities in synaptosomes and platelets and parameters of oxidative stress in rats experimentally demyelinated. Brain Res Bull 2009, 80:45-51.
67. Spanevello R.M., Mazzanti C.M., Bagatini M., Correa M., Schmatz R., Stefanello N., Thomé G., Morsch V.M., Becker L., Bellé L., de Oliveira L., Schetinger M.R. Activities of the enzymes that hydrolyze adenine nucleotides in platelets from multiple sclerosis patients. J Neurol 2010, 257:24-30.
68. Spanevello R.M., Mazzanti C.M., Schmatz R., Thomé G., Bagatini M., Correa M., Rosa C., Stefanello N., Bellé L.P., Moretto M.B., Oliveira L., Morsch V.M., Schetinger M.R. The activity and expression of NTPDase is altered in lymphocytes of multiple sclerosis patients. Clin Chim Acta 2010, 411:210-214.
69. Tayebati S.K., El-Assouad D., Ricci A., Amenta F. Immunochemical and immunocytochemical characterization of cholinergic markers in human peripheral blood lymphocytes. J Neuroimmunol 2002, 132:147-155.
70. Thomé G.R., Oliveira L.S., Schetinger M.R., Morsch V.M., Spanevello R.M., Fiorenza A.M., Seres J., Baldissarelli J., Stefanello N., Pereira M.E., Calgaroto N.S., Pimentel V.C., Leal D.B., Souza V.do C., Jaques J.A., Leal C.A., Cruz R.C., Thiesen F.V., Melazzo Mazzanti C. Nicotine alters the ectonucleotidases activities in lymphocytes: in vitro and in vivo studies. Biomed Pharmacother 2012, 66:206-212.
71. van Westerloo D.J. The vagal immune reflex: a blessing from above. Wien Med Wochenschr 2010, 160:112-117.
72. Voelter W., Zech K., Arnold P., Ludwig G. Determination of selected pyrimidines, purines and their metabolites in serum and urine by reversed-phase ion-pair chromatography. J Chromatogr 1980, 199:345-354.
73. Worek F., Mast U., Kiderlen D., Diepold C., Eyer P. Improved determination of acetylcholinesterase activity in human whole blood. Clin Chim Acta 1999, 288:73-90.
74. Yegutkin G.G. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta 2008, 1783:673-694.
75. Zanini D., Schmatz R., Pelinson L.P., Pimentel V.C., da Costa P., Cardoso A.M., Martins C.C., Schetinger C.C., Baldissareli J., do Carmo Araújo M, Oliveira L., Chiesa J., Morsch V.M., Leal D.B., Schetinger M.R. Ectoenzymes and cholinesterase activity and biomarkers of oxidative stress in patients with lung cancer. Mol Cell Biochem 2013, 374:137-148.
76. Zimmermann H. ATP and acetylcholine, equal brethren. Neurochem Int 2008, 52:634-648.